1. 1459PWhich of afatinib and gefitinib/erlotinib is the better EGFR-TKI to be followed by osimertinib?. (23rd October 2018) Authors: Tamiya, M; Tamiya, A; Suzuki, H; Nakahama, K; Taniguchi, Y; Kunimasa, K; Kimura, M; Inoue, T; Nishino, K; Hirashima, T; Atagi, S; Imamura, F; Kumagai, T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 314PAssociation of immune-related adverse events and efficacy in Japanese patients with squamous cell carcinoma of the head and neck treated with nivolumab. (25th November 2018) Authors: Otsuka, T; Fujiishi, K; Matsumoto, K; Kimura, T; Koike, R; Cho, H; Hasegawa, A; Nishio, M; Otozai, S; Yoshii, T; Kudo, T; Fujisawa, F; Sugimoto, N; Yagi, T; Imamura, F; Fujii, T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 502PEpidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study. (24th November 2019) Authors: Kanazu, M; Mori, M; Shiroyama, T; Nagatomo, I; Ihara, S; Komuta, K; Suzuki, H; Hirashima, T; Kimura, M; Imamura, F Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 507PImmune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study. (24th November 2019) Authors: Uenami, T; Mori, M; Shiroyama, T; Nagatomo, I; Ihara, S; Komuta, K; Suzuki, H; Hirashima, T; Kimura, M; Imamura, F Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. BSC (biological soil crust) Method for soil erosion control and vegetation recovery: Case studies in Japan. Issue 1 (1st November 2022) Authors: Nguyen, T C T; Md Khudzari, J; Imamura, F; Sethi, S; Iwamoto, K Journal: IOP conference series Issue: Volume 1091:Issue 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. LBA16Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis. (24th November 2019) Authors: Cho, B C; Ohe, Y; Zhou, C; Reungwetwattana, T; Cheng, Y; Chewaskulyong, B; Lee, K H; Planchard, D; Vansteenkiste, J F; Gray, J E; Shah, R; Cheema, P K; Tiseo, M; John, T; Hodge, R; Rukazenkov, Y; Soria, J-C; Lin, M-C; Imamura, F; Ramalingam, S S Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. (23rd October 2018) Authors: Ramalingam, S S; Cheng, Y; Zhou, C; Ohe, Y; Imamura, F; Cho, B C; Lin, M-C; Majem, M; Shah, R; Rukazenkov, Y; Todd, A; Markovets, A; Barrett, J C; Chmielecki, J; Gray, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. LBA8Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. (25th November 2018) Authors: Cho, B C; Cheng, Y; Zhou, C; Ohe, Y; Imamura, F; Lin, M-C; Majem, M; Shah, R; Rukazenkov, Y; Todd, A; Markovets, A; Barrett, C; Chmielecki, J; Gray, J E; Ramalingam, S S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. OP36 Trans fatty acid biomarkers and incident type 2 diabetes: pooled analysis of 10 prospective cohort studies in the fatty acids and outcomes research consortium (FORCE). (3rd September 2019) Authors: Lai, HTM; Imamura, F; Ardisson Korat, AV; Murphy, R; Tintle, NL; Bassett, J; Chen, J; Kroeger, J; Forouhi, NG; Schulze, MB; Harris, WS; Vasan, RS; Hu, FB; Lemaitre, RN; Giles, GG; Djousse, L; Brouwer, I; Wu, JHY; Marklund, M; Micha, R Journal: Journal of epidemiology and community health Issue: Volume 73(2019)Supplement 1 Page Start: A17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗